News

Masonic Cancer Center Articles

Robert Kratzke, MD

U of M opens a new clinical trial studying the effects of COVID-19 on cancer patients

The University of Minnesota, which is already at the forefront of COVID-19 research, has opened a new trial to study the short and long-term effects of the novel coronavirus on cancer patients. The study is a partnership between the…
Ilana Chefetz

Research breakthrough on specific form of cell death may overcome chemoresistance

Institute researchers find evidence in favor of necroptotic therapies November 2, 2020 (Austin, Minn.) – Dr. Ilana Chefetz, head of the Cancer Stem Cells & Necroptosis lab at The Hormel Institute, published a review article focusing…
The Hormel Institute

Breakthrough research using light-activated proteins for targeted therapy

Discoveries may impact future brain tumor therapy and treatment for hospital-acquired infections October 27, 2020 (Austin, Minn.) –  The Nucleotide Metabolism & Drug Discovery lab at The Hormel Institute, led by Dr. Jarrod French…
The Hormel Institute

Breakthrough research using light-activated proteins for targeted therapy

Discoveries may impact future brain tumor therapy and treatment for hospital-acquired infections October 27, 2020 (Austin, Minn.) –  The Nucleotide Metabolism & Drug Discovery lab at The Hormel Institute, led by Dr. Jarrod French…
Phase I/II Clinical Trials

U of M opens first of its kind Phase I/II clinical trial to treat metastatic gastrointestinal epithelial cancer using CRISPR edited immune cells

The University of Minnesota has opened a new and innovative clinical trial for the treatment of metastatic gastrointestinal epithelial cancer. The Phase I/II clinical trial, which will use the revolutionary CRISPR/Cas9 System, has opened…

U of M opens first of its kind Phase I/II clinical trial to treat metastatic gastrointestinal epithelial cancer using CRISPR edited immune cells

MINNEAPOLIS, MN - The University of Minnesota has opened a new and innovative clinical trial for the treatment of metastatic gastrointestinal epithelial cancer. The Phase I/II clinical trial, which will use the revolutionary CRISPR/…
Microscope and gloved hand

U of M opens first of its kind Phase I/II clinical trial to treat metastatic gastrointestinal epithelial cancer using CRISPR edited immune cells

MINNEAPOLIS, MN - The University of Minnesota has opened a new and innovative clinical trial for the treatment of metastatic gastrointestinal epithelial cancer. The Phase I/II clinical trial, which will use the revolutionary CRISPR/…
Masonic Cancer Center Logo

University of Minnesota Researchers Awarded $2.06M Grant from The NCI

Leaders in the Program in Health Disparities Research (PHDR) and the Masonic Cancer Center, University of Minnesota recently received a $2,063,688 award from the National Cancer Institute/National Institutes of Health for their R25 project…
Shernan Holtan, MD

FDA Grants Orphan Drug Designation for New Treatment for Life-Threatening Acute GVHD Developed at the University of Minnesota

The FDA has granted Orphan Drug Designation to urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF, most commonly available as Pregnyl®) for the treatment of acute graft-versus-host-disease (GVHD). This…
David Ingbar, MD, and John E. Wagner, MD

University of Minnesota opens clinical trial for new treatment of COVID-19

A patient with COVID-19 and lung failure at the University of Minnesota is the first to be treated in the U.S. on a new FDA-approved clinical trial determining the safety and effectiveness of mesenchymal stem cells (MSCs). This new…